CTLA4 and hepatocellular carcinoma: At least for ELOVL1, a higher expression in hepatocellular carcinoma results in cancer immune evasion, including an increased expression of programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) [67].